Answers are grounded in this paper and cite their sources.
While melanoma is not as common as other types of skin cancer among the whole dermatologic cancer category, it appears to be extremely aggressive for its high death rates. Conventional treatments like radiation therapy (RT), chemotherapy, and surgery have showed either significant side effects or limited improvement to the disease. Ipilimumab, anti-CTLA-4 antibodies, is immune checkpoint Inhibitor (ICI) approved by the FDA for being one source of treatment in the advanced melanoma in 2011 as an immunotherapeutic approach. Anti-CTLA-4 is authorized for usage as monotherapy treatment for advanced metastatic melanoma. it licensed as combination treatment for melanoma. The new study shown that the ipilimumab combined with pembrolizumab may be feasible in treating more cancerous diseases. For individuals that suffer from advanced malignant melanoma, ipilimumab decrease the overall death rates in randomized trials. The combined approach of anti-PD-1 and anti-CTLA-4 antibodies has shown feasibility.
No takes yet. Share an insight, caveat, or question.
Yumeng Yan (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: